Skip to content

Effect of adding supermint and camellia sinensis to the routine treatment of patients with helicobacter pylori infection

Effect of adding supermint and camellia sinensis to the routine treatment of patients with helicobacter pylori infection a double-blind clinical trial study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200422047167N1
Enrollment
40
Registered
2025-12-05
Start date
2025-12-22
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection.

Interventions

Intervention 1: Intervention group: In addition to standard treatment, patients in this group will also take two herbal medicines, Camellia sinensis (green tea) and Supermint (mint tablets), for one m

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with H. pylori who have a positive written Urea Breath Test or Stool Antigen test result Patients who have not received any anti-H. pylori treatment in the past three months

Exclusion criteria

Exclusion criteria: People who do not have a confirmed test and a written positive H. pylori result. People who have been treated for H. pylori infection in the past Patients who have taken antibiotics for any reason in the past three months. Patients with known allergies to herbal ingredients used in the study (supermint and camellia sinensis) People with severe underlying diseases such as gastrointestinal cancers, advanced liver disease, or kidney failure. Pregnant or breastfeeding women

Design outcomes

Primary

MeasureTime frame
Percentage of people whose anti H.Pylori IgG stool antigen test results changed after treatment. Timepoint: Before starting treatment and after completing the treatment period (one month), 5 cc blood samples and stool samples will be taken from all patients to test for IgG Antibody and Stool Antigen. Method of measurement: Helicobacter pylori antigen determination in feces is performed with a special kit and anti-H.pylori IgG level is measured using ELISA.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedeh Azra Shamsdin

Shiraz University of Medical Sciences

shamsdina@sums.ac.ir+98 71 3628 1442

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026